CN111836896A - 免疫逃避载体及其在基因治疗中的用途 - Google Patents

免疫逃避载体及其在基因治疗中的用途 Download PDF

Info

Publication number
CN111836896A
CN111836896A CN201980018276.3A CN201980018276A CN111836896A CN 111836896 A CN111836896 A CN 111836896A CN 201980018276 A CN201980018276 A CN 201980018276A CN 111836896 A CN111836896 A CN 111836896A
Authority
CN
China
Prior art keywords
enveloped
viral vector
aav
vector
enveloped viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980018276.3A
Other languages
English (en)
Chinese (zh)
Inventor
G·温斯洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chameleon Biotechnology Co ltd
Original Assignee
Chameleon Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chameleon Biotechnology Co ltd filed Critical Chameleon Biotechnology Co ltd
Publication of CN111836896A publication Critical patent/CN111836896A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00051—Methods of production or purification of viral material
    • C12N2750/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980018276.3A 2018-01-11 2019-01-11 免疫逃避载体及其在基因治疗中的用途 Pending CN111836896A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862616167P 2018-01-11 2018-01-11
US62/616,167 2018-01-11
US201862768779P 2018-11-16 2018-11-16
US62/768,779 2018-11-16
PCT/US2019/013361 WO2019140311A1 (en) 2018-01-11 2019-01-11 Immuno-evasive vectors and use for gene therapy

Publications (1)

Publication Number Publication Date
CN111836896A true CN111836896A (zh) 2020-10-27

Family

ID=65444323

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018276.3A Pending CN111836896A (zh) 2018-01-11 2019-01-11 免疫逃避载体及其在基因治疗中的用途

Country Status (14)

Country Link
US (1) US20200338216A1 (https=)
EP (1) EP3737768A1 (https=)
JP (2) JP7406253B2 (https=)
KR (1) KR20200128519A (https=)
CN (1) CN111836896A (https=)
AU (1) AU2019206639A1 (https=)
BR (1) BR112020014093A2 (https=)
CA (1) CA3088897A1 (https=)
CL (1) CL2020001850A1 (https=)
IL (1) IL275951A (https=)
MX (1) MX2020007390A (https=)
RU (1) RU2020126574A (https=)
SG (1) SG11202006298XA (https=)
WO (1) WO2019140311A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4118219A4 (en) * 2020-03-11 2024-04-17 Shanghai Belief-Delivery Biomed Co., Ltd. Novel use of aspirin compound in increasing nucleic acid expression
US20230355803A1 (en) * 2020-06-24 2023-11-09 Chameleon Biosciences, Inc. Extracellular vesicles with immune modulators
CN112410304A (zh) * 2020-11-12 2021-02-26 天津大学 一种基因修饰的外泌体及其制备方法和应用
WO2023028035A1 (en) * 2021-08-23 2023-03-02 University Of Florida Research Foundation, Incorporated Lipid enveloped recombinant aav particles for gene therapy use
EP4660308A1 (en) * 2023-01-31 2025-12-10 Synplogen Co., Ltd. Helper gene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518050A (ja) * 1998-06-19 2002-06-25 メディジーン・アクチェンゲゼルシャフト Ａａｖの構造タンパク質、その製造及び用途
CN104887717A (zh) * 2015-06-04 2015-09-09 爱康得生物医学技术（苏州）有限公司 一种免疫增强试剂
WO2017136764A1 (en) * 2016-02-05 2017-08-10 The General Hospital Corporation Hybrid system for efficient gene delivery to cells of the inner ear

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8672198A (en) 1997-07-31 1999-02-22 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
WO1999055893A1 (en) 1998-04-29 1999-11-04 University Of Southern California Retroviral vectors including modified envelope escort proteins
EP1769078A1 (en) * 2004-07-01 2007-04-04 VIRxSYS Corporation Vector packaging cell line
WO2006138670A2 (en) 2005-06-16 2006-12-28 Virxsys Corporation Antibody complexes
JP4691611B1 (ja) 2010-01-15 2011-06-01 富士フイルム株式会社 有機電界発光素子
WO2011106376A2 (en) * 2010-02-23 2011-09-01 The General Hospital Corporation Use of microvesicles in the treatment of medical conditions
JP7242180B2 (ja) * 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518050A (ja) * 1998-06-19 2002-06-25 メディジーン・アクチェンゲゼルシャフト Ａａｖの構造タンパク質、その製造及び用途
US20070238684A1 (en) * 1998-06-19 2007-10-11 Medigene Aktiengesellschaft AAV scleroprotein, production and use thereof
CN104887717A (zh) * 2015-06-04 2015-09-09 爱康得生物医学技术（苏州）有限公司 一种免疫增强试剂
WO2017136764A1 (en) * 2016-02-05 2017-08-10 The General Hospital Corporation Hybrid system for efficient gene delivery to cells of the inner ear

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADRIOUCH S, ET AL.: "Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer" *
CASEY A MAGUIRE, ET AL.: "Microvesicle-associated AAV Vector as a Novel Gene Delivery System" *
ELOISE HUDRY, ET AL.: "Exosome-associated AAV vector as a robust and convenient neuroscience tool" *
GYÖRGY B, ET AL: "Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo" *

Also Published As

Publication number Publication date
KR20200128519A (ko) 2020-11-13
US20200338216A1 (en) 2020-10-29
JP2021510522A (ja) 2021-04-30
WO2019140311A1 (en) 2019-07-18
BR112020014093A2 (pt) 2020-12-01
EP3737768A1 (en) 2020-11-18
MX2020007390A (es) 2020-10-14
JP7406253B2 (ja) 2023-12-27
AU2019206639A1 (en) 2020-08-20
CA3088897A1 (en) 2019-07-18
IL275951A (en) 2020-08-31
JP2023160938A (ja) 2023-11-02
CL2020001850A1 (es) 2020-12-04
SG11202006298XA (en) 2020-07-29
RU2020126574A (ru) 2022-02-11

Similar Documents

Publication Publication Date Title
AU2022200502B2 (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
JP7406253B2 (ja) 免疫回避性ベクターおよび遺伝子療法のための使用
US11999965B2 (en) Bocaparvovirus small noncoding RNA and uses thereof
US20240042058A1 (en) Tissue-specific methods and compositions for modulating a genome
US20230355803A1 (en) Extracellular vesicles with immune modulators
AU2023253700A1 (en) Use of an irak4 modulator for gene therapy
CN117642173A (zh) 用于诱导对基因递送靶媒剂的免疫耐受性的方法和试剂盒
Reul Viral gene transfer systems for cancer immunotherapy: semireplication-competent VSV and receptor-targeted AAV for the delivery of immunomodulatory proteins
Martin Development and Characterisation of HEK293T Cell Expression Systems for Enhanced Production of Recombinant AAV Viral Vectors
WO2025193808A1 (en) Cns-specific gene replacement therapy for genetic forms of als/ftd
HK40104471A (zh) 用於目的基因的表达盒及其应用
Reul Viral gene transfer systems for cancer immunotherapy
HK40049414A (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
HK1240977B (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
HK1240977A1 (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201027